Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Baxter
Dow
Harvard Business School
Boehringer Ingelheim

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR GADOTERIDOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Gadoteridol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00522951 ↗ SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study Completed Bayer Phase 3 2007-08-01 This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.
NCT01613417 ↗ Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed Bracco Diagnostics, Inc Phase 4 2012-08-01 This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two MR contrast agents.
NCT02359097 ↗ Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma Completed National Cancer Institute (NCI) N/A 2015-01-06 This clinical trial studies steady state blood volume maps using ferumoxytol non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor cells and the blood vessels in and around the tumors.
NCT02359097 ↗ Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma Completed Oregon Health and Science University N/A 2015-01-06 This clinical trial studies steady state blood volume maps using ferumoxytol non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor cells and the blood vessels in and around the tumors.
NCT02359097 ↗ Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma Completed OHSU Knight Cancer Institute N/A 2015-01-06 This clinical trial studies steady state blood volume maps using ferumoxytol non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor cells and the blood vessels in and around the tumors.
NCT02481882 ↗ Baseline Cortical Haemodynamics in MS Unknown status University of Nottingham N/A 2017-01-01 This study will provide information on cortical haemodynamics in MS patients to address the discrepancies reported in previous literature, allowing further insight into the role of haemodynamics in the disease. It will also instruct us as to the most effective scanning protocols for future research. Developing a suitable protocol for studying perfusion longitudinally may also enable identification of new therapeutic interventions to normalise any perfusion abnormalities in MS patients.
NCT03057561 ↗ Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance Unknown status Guerbet N/A 2016-10-01 This project is designed to demonstrate equivalence of Dotarem enhanced LGE-CMR (late gadolinium enhancement cardiac MRI) with Gadoviost enhanced LGE-CMR from the standpoint of visual image quality, quantitative image quality, and association with clinical outcomes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gadoteridol

Condition Name

Condition Name for Gadoteridol
Intervention Trials
Multiple Sclerosis 2
Diffuse Intrinsic Pontine Glioma 2
Glioblastoma 2
Adult Brain Glioblastoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gadoteridol
Intervention Trials
Glioma 3
Neoplasm Metastasis 2
Breast Neoplasms 2
Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gadoteridol

Trials by Country

Trials by Country for Gadoteridol
Location Trials
United States 15
Japan 11
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gadoteridol
Location Trials
Alabama 2
California 2
Arizona 1
New York 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gadoteridol

Clinical Trial Phase

Clinical Trial Phase for Gadoteridol
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gadoteridol
Clinical Trial Phase Trials
Completed 5
Recruiting 4
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gadoteridol

Sponsor Name

Sponsor Name for Gadoteridol
Sponsor Trials
Sabine Mueller, MD, PhD 2
University of Alabama at Birmingham 2
Guerbet 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gadoteridol
Sponsor Trials
Other 17
Industry 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
Mallinckrodt
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.